I’ll identify critical success factors early & build the commercial bridge from Phase Ib to market readiness before the Phase III readout.
Our proprietary Bridge Roadmap provides a clear sight line into US commercialization including a highly detailed view of all Commercial & Medical Affairs imperatives, critical success factors and FTEs (e.g., Sales & total Commercial/Medical Affairs) from T-48 through the launch year.
The Bridge Roadmap aligns the size of the Commercial & Medical Affairs "effort” (costs & FTEs) with five-year post launch revenues in the US and stage gates the spend with company milestones.
Take the chaos out of the equation. I’ll prioritize and build your key components with phase specific expertise, for on target, on time and on budget execution.
Stepping into an emerging biotech company and seamlessly transitioning from R&D to Commercial is the kind of leadership you expect. That’s what Bridge delivers and then some. Not just establish but safeguard commercial alignment with Executive Team and Board on strategy, critical success factors and budget, personally executing all your imperatives up to the best qualified CCO onboarding.
Thirty plus years of experience and expertise with over a hundred biotech companies brings you the kind of relational world class Commercial & Medical Affairs experts you’ll need (e.g., Market Access, Pricing & Reimbursement, HEOR, Publication Planning etc.) for just-in-time engagement that collaboratively executes your commercial plan strategically, sustainably and affordably.
To execute key commercial imperatives you’ll need access to big company experts that will work for small company pricing.
Intrinsic value is defined as an estimate of the actual true value of a company, regardless of market value. At Bridge, we measure our “actual true value” in our ability to make our clients shine in the transition to a commercial company. Additional factors your company should consider when making a commercial leadership choice are in what may be called “hidden intrinsic value” and include: Value for money, just in time experts without overhead, fiduciary responsibility and not having to terminate a CCO are just a few.
Being the founder & CEO of Bridge as your iCCO means single point of contact communications with full accountability for all your commercialization challenges until the CCO is hired.
Being the founder & CEO of Bridge as your iCCO means single point of contact communications with full accountability for all your commercialization challenges until the CCO is hired. From day one, I’ll dive deep into your operations so that I can make informed “in the moment” critical recommendations and decisions in an everchanging development, regulatory and competitive marketplace.
This immersion enables keen insight generation that are specific to your company, product, market and often lead to “game changing” solutions.
Wonderful, wonderful Copenhagen! Companies in Copenhagen have a strong focus on medical applications in areas like cancer and diabetes, as well as a lot of activity in industrial biotech. (labiotech.eu)
With all the progress made in oncology therapeutics, cancer drug resistance remains a large unmet clinical need. Shining a spotlight on a biotech company aiming to understand the molecular and cellular processes associated with resistance.
Scandion Oncology, based on Copenhagen, Denmark, have developed a framework for understanding drug resistance. Resistance may be an intrinsic property of some cells or clones in a tumor. Over time upon treatment with a cancer drug, these cells are enriched in the tumor, such that the entire tumor becomes resistant to the treatment (this is called intrinsic resistance).
Another concept of resistance is known as acquired resistance. Here, tumor cells progress through a number of genetic events. Accumulation of defects and genetic changes will eventually make the tumor cells resistant to treatment. Over time and upon treatment, only resistant tumor cells will remain, and the entire tumor will become resistant to treatment.
Led by President and CEO Bo Rode Hansen and COO Maj Hedtjarn, Scandion has two products currently in development. CORIST, for the treatment of drug resistant metastatic colorectal cancer is a clinical Phase II study. The second program, PANTAX, for the treatment of unresectable or metastatic pancreatic cancer is a clinical Phase Ib study. In fact, this month they announced a better-than-expected tolerability of its potential new cancer treatment SCO-101 in the dose-finding PANTAX phase 1b-trial. Thus, dosing is now escalated to higher levels than expected based on the initial findings in the CORIST trial
Using their proprietary DEN50-R platform they can efficiently screen non-resistant and resistant cancer cells simultaneously, providing unprecedented insights into cancer drug resistance mechanisms in a streamlined fashion.
Looking forward to more products from Scandion Oncology to accelerate effective cancer treatments.
More News & Events